Magle Chemoswed Holding AB (MAGLE)
Market Closed
10 Aug, 15:25
XSTO XSTO Primary 
XSTU kr
0. 50
+0.02
+4.1667%
kr
11.15M Market Cap
34.47 P/E Ratio
- Div Yield
1,500 Volume
0.4 Eps
kr 0.48
Previous Close Want to track MAGLE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MAGLE closed today higher at kr0.5, an increase of 4.1667% from yesterday's close, completing a monthly decrease of -88.6364% or -kr3.9. Over the past 12 months, MAGLE stock lost -97.1429%.
MAGLE is not paying dividends to its shareholders.
The last earnings report, released on Mar 27, 2026, missed the consensus estimates by -0.1%. On average, the company has fell short of earnings expectations by -0.6333%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSTO (SEK).
Magle Chemoswed Holding AB (MAGLE) FAQ
What is the stock price today?
The current price is kr0.50.
On which exchange is it traded?
Magle Chemoswed Holding AB is listed on XSTO.
What is its stock symbol?
The ticker symbol is MAGLE.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 11.15M.
Has Magle Chemoswed Holding AB ever had a stock split?
No, there has never been a stock split.
Magle Chemoswed Holding AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Aaron Wong CEO | XSTO Exchange | SE0014401014 ISIN |
| SE Country | 150 Employees | - Last Dividend | 29 Nov 2024 Last Split | - IPO Date |
Overview
Magle Chemoswed Holding AB (publ) is a renowned contract development and manufacturing organization dedicated to serving the pharmaceutical and medical device industries in Sweden. With its subsidiaries, the company embarks on process development and the manufacture of active pharmaceutical ingredients (APIs). Furthermore, it delves into research, development, and production within wound care and diagnostics, emphasizing products grounded in degradable starch microspheres technology. Founded in 1944 and based in Malmö, Sweden, Magle Chemoswed operates under the umbrella of Magle AB, showcasing a deep-rooted history and expertise in the pharmaceutical production and medical device domain.
Products and Services
Magle Chemoswed offers a diverse range of products and services, including:
- Active Pharmaceutical Ingredients (APIs): The company manufactures key pharmaceutical compounds such as warfarin sodium for anticoagulation, melperone hydrochloride as an antipsychotic agent, isradipine for hypertension, amantadine sulfate for central nervous system disorders, and benserazide hydrochloride for Parkinson's disease treatment in combination with L-Dopa.
- Medical Devices: Magle Chemoswed produces medical devices for various applications including:
- EmboCept S: A microsphere-based medical device aimed at the vascular occlusion of liver and lung tumors.
- SmartGel: A non-allergenic hydrogel utilizing the company's proprietary microsphere technology, designed for advanced wound care applications.
- SmartPAN: A medical device intended for the detection of pancreatic fluid leakage during surgical procedures, whether open or minimally invasive.
- Development Projects: The company is also engaged in the development of innovative medical devices including:
- EmboCept M: A product in development for treating benign prostatic hyperplasia.
- EmboCept L: A device under development for the treatment of uterine fibroids.
- SmartGel II: An advanced wound care hydrogel designed for the removal and prevention of wound biofilm.
- SmartBone: An innovative formulation combining microspheres with active ingredients to stimulate bone growth in surgical implant procedures.
Contact Information
Address: AgneslundsvAegen 27, Malmö, Sweden, 212 15
Phone: 46 40 38 33 00
Website: https://www.maglechemoswed.com
